导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.83% | 2421/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -5.23% | 3113/5421 |
| 近一季 | -7.86% | 2556/5209 |
| 近半年 | -2.33% | 1861/4920 |
| 近一年 | 3.43% | 1936/4366 |
| 近两年 | 52.80% | 1399/2954 |
| 近三年 | 36.82% | 807/2253 |
| 成立以来 | 149.99% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.29% 3111/4961 |
15.00% 1726/5312 |
- - |
- - |
| 2025 | 24.90% 1756/4813 |
0.93% 1734/3635 |
1.36% 2369/4076 |
21.46% 1791/4524 |
0.53% 1956/4813 |
| 2024 | 18.56% 593/3463 |
2.99% 641/2808 |
-0.63% 802/3014 |
17.63% 1157/3129 |
-1.51% 1735/3463 |
| 2023 | -8.65% 1040/2656 |
3.91% 1095/2280 |
-3.77% 891/2385 |
-2.49% 683/2515 |
-6.32% 1720/2655 |
| 2022 | -18.27% 682/2207 |
-13.32% 736/1919 |
8.27% 375/2016 |
-14.15% 1034/2113 |
1.44% 1265/2208 |
| 2021 | -1.05% 777/1822 |
-3.02% 742/1255 |
3.61% 964/1330 |
-4.20% 688/1466 |
2.79% 515/1822 |
| 2020 | 41.11% 296/1250 |
-8.41% 607/1028 |
13.15% 646/1067 |
16.32% 157/1164 |
17.06% 139/1184 |
| 2019 | 44.87% 162/1092 |
25.89% 438/754 |
3.39% 49/804 |
4.12% 216/850 |
6.90% 521/918 |
| 2018 | -18.32% 142/834 |
- - |
- - |
- - |
-11.85% 365/691 |
| 2017 | 36.16% 33/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.62% 177/605 |
- - |
- - |
- - |
- - |
| 2015 | -0.19% 257/575 |
- - |
- - |
- - |
- - |
| 2014 | 59.24% 36/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.33% 155/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.52% 31/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.12% 27/102 |
- - |
- - |
- - |
- - |
| 2010 | -18.48% 50/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 诺安中证A100指数A VS. 长安沪深300非周期A(740101) |